Pharmaceutical Supplier – Dantrolene Sodium for Injection

The contract solicits the supply of sterile, lyophilized Dantrolene Sodium for Injection, USP, specifically designated for emergency medical use and required to meet stringent regulatory standards including FDA compliance, current Good Manufacturing Practices, and defined shelf-life parameters. The product must be manufactured and packaged to ensure stability, purity, and readiness for immediate deployment in critical care scenarios, with all documentation and labeling adhering to federal pharmaceutical requirements. This is a subcontract under the Department of Defense, managed by the MEDICAL SUPPLY CHAIN PHARM FSA, with performance required at Fort Bragg, North Carolina, 28310. The solicitation was posted on July 26, 2026, with a response deadline of August 3, 2026, targeting qualified pharmaceutical suppliers capable of meeting the technical, regulatory, and logistical demands of emergency medical procurement. The North American Industry Classification System code 325412 indicates the scope is within pharmaceutical preparation manufacturing. There is no set-aside designation specified, and the opportunity is open to eligible subcontractors with proven capacity to deliver compliant, high-integrity Dantrolene Sodium products in a timely and reliable manner, ensuring continuous availability for military and emergency medical operations.